Meeder Asset Management Inc. Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Meeder Asset Management Inc. acquired a new position in Janux Therapeutics, Inc. (NASDAQ:JANX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,972 shares of the company’s stock, valued at approximately $159,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Intech Investment Management LLC bought a new stake in shares of Janux Therapeutics in the 3rd quarter valued at $368,000. Charles Schwab Investment Management Inc. grew its holdings in Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after acquiring an additional 156,675 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Janux Therapeutics by 27.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 30,595 shares of the company’s stock worth $1,390,000 after acquiring an additional 6,547 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Janux Therapeutics by 40.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after purchasing an additional 721,563 shares during the period. Finally, Polar Asset Management Partners Inc. bought a new stake in shares of Janux Therapeutics during the 3rd quarter valued at about $613,000. 75.39% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on JANX shares. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Leerink Partners raised their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a report on Tuesday, December 3rd. BTIG Research upped their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Wedbush restated an “outperform” rating and issued a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Janux Therapeutics in a research note on Monday, March 3rd. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $92.44.

Janux Therapeutics Stock Performance

Shares of JANX opened at $27.00 on Tuesday. Janux Therapeutics, Inc. has a 52 week low of $26.40 and a 52 week high of $71.71. The stock has a 50 day moving average price of $35.33 and a two-hundred day moving average price of $45.87. The firm has a market capitalization of $1.60 billion, a P/E ratio of -23.08 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Activity

In related news, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David Alan Campbell sold 5,000 shares of Janux Therapeutics stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the sale, the chief executive officer now owns 293,054 shares in the company, valued at $17,583,240. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 25,002 shares of company stock worth $1,279,953 over the last quarter. Insiders own 29.40% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.